OverviewSuggest Edit

AstraZeneca is a global science-led biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. It develops drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology. The company offers its products to primary care and specialty care physicians through distributors and local representative offices.

TypePublic
Founded1999
HQCambridge, GB
Websiteastrazeneca.com
Employee Ratings3.9
Culture scoreB

Latest Updates

Employees (est.) (Dec 2019)70,600(+10%)
Job Openings2,439
Revenue (FY, 2019)$24.4 B(+11%)
Share Price (May 2020)£8.7 K(-1%)

Key People/Management at AstraZeneca

Pascal Soriot

Pascal Soriot

Executive Director and CEO
Mark Cobbold

Mark Cobbold

Vice President, Discovery, Oncology R&D
Anand Subramony

Anand Subramony

Vice President, Antibody Discovery and Protein Engineering, R&D
Marc Dunoyer

Marc Dunoyer

Executive Director and Chief Financial Officer
Maria Belvisi

Maria Belvisi

Senior Vice President and Head of Research and Early Development, Respiratory, Inflammation and Autoimmunity, BioPharmaceuticals R&D
Graham Chipchase

Graham Chipchase

Senior Independent Non-Executive Director
Show more

AstraZeneca Office Locations

AstraZeneca has offices in Cambridge, London, Luton, Park Estate and in 241 other locations
Cambridge, GB (HQ)
Francis Crick Ave, Trumpington
London, GB
15 Stanhope Gate
Luton, GB
600 Capability Green
Park Estate, GB
Alderley House, Alderley Park
Royston, GB
Cambridge Rd
Saffron Walden, GB
Unnamed Road
Show all (258)

AstraZeneca Financials and Metrics

AstraZeneca Revenue

Embed Graph
View revenue for all periods
AstraZeneca's revenue was reported to be $24.38 b in FY, 2019 which is a 10.4% increase from the previous period.
USD

Revenue (Q1, 2020)

6.4b

Gross profit (Q1, 2020)

4.9b

Gross profit margin (Q1, 2020), %

77.7%

Net income (Q1, 2020)

750.0m

EBIT (Q1, 2020)

1.2b

Market capitalization (15-May-2020)

113.8b

Closing stock price (15-May-2020)

8.7k

Cash (31-Mar-2020)

3.4b

EV

128.9b
AstraZeneca's current market capitalization is £113.8 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

22.5b22.1b24.4b

Revenue growth, %

(2%)(2%)10%

Cost of goods sold

4.3b4.9b4.9b

Gross profit

18.1b17.2b19.5b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

5.4b5.1b6.2b5.2b5.2b5.3b5.5b5.8b6.4b6.4b

Cost of goods sold

894.0m950.0m1.2b1.1b1.0b1.2b1.1b1.1b1.4b1.4b

Gross profit

4.5b4.1b5.0b4.0b4.1b4.2b4.4b4.8b5.1b4.9b

Gross profit Margin, %

83%81%80%78%80%78%79%82%79%78%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

3.3b4.8b5.4b

Accounts Receivable

2.8b3.0b3.6b

Inventories

3.0b2.9b3.2b

Current Assets

13.2b15.6b15.6b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

3.1b5.2b4.0b3.0b3.0b3.4b4.1b5.4b4.0b3.4b

Inventories

2.7b2.9b3.2b3.3b3.1b3.0b3.1b3.2b3.1b3.1b

Current Assets

11.6b14.3b13.6b13.2b12.4b13.1b13.6b15.2b13.5b12.8b

PP&E

7.0b7.1b7.3b7.7b7.5b7.6b7.4b7.4b7.3b7.3b
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

2.9b2.1b1.2b

Depreciation and Amortization

3.0b3.8b3.8b

Inventories

(548.0m)(13.0m)(316.0m)

Accounts Payable

415.0m(103.0m)868.0m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

512.0m958.0m1.6b316.0m635.0m1.0b563.0m670.0m950.0m750.0m

Depreciation and Amortization

658.0m1.3b1.9b709.0m1.4b2.1b676.0m1.4b2.1b841.0m

Cash From Operating Activities

88.0m338.0m2.6b(140.0m)(75.0m)394.0m(387.0m)491.0m1.6b139.0m

Purchases of PP&E

(286.0m)(549.0m)(849.0m)(213.0m)(486.0m)(728.0m)(174.0m)(438.0m)(659.0m)(186.0m)
USDY, 2020

EV/EBIT

105.7 x

EV/CFO

927.7 x

Debt/Equity

1.5 x

Debt/Assets

0.3 x

Financial Leverage

4.7 x
Show all financial metrics

AstraZeneca Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Projects in R&D Pipeline

99 133 146 132 144 149 167

Phase I Trials Projects

33 24 44 41 50 38 34

Phase II Trials Projects

27 11 33 36 37 43 50

Phase III Trials Projects

19 11 35 27 23 22 27
Show all operating metrics

AstraZeneca Acquisitions / Subsidiaries

Company NameDateDeal Size
Takeda Respiratory BusinessApril 16, 2016$575 m
AcertaPharmaDecember 17, 2015$4 b
ZS PharmaNovember 06, 2015$2.70 b
AlmirallJuly 30, 2014
Pearl TherapeuticsJune 10, 2013$1.20 b
Omthera PharmaceuticalsMay 29, 2013$323 m
Ardea BiosciencesApril 23, 2012$781 m
Guangdong BeiKang Pharmaceutical Company LtdDecember 08, 2011
NovexelDecember 23, 2009
Arrow TherapeuticsFebruary 01, 2007$150 m
Show more

AstraZeneca Revenue Breakdown

Embed Graph

AstraZeneca revenue breakdown by business segment: 10.7% from Other Disease Areas, 22.1% from Respiratory, Inflammation and Autoimmunity, 35.5% from Oncology, 28.3% from Cardiovascular and Metabolic Diseases and 3.4% from Other

AstraZeneca revenue breakdown by geographic segment: 17.1% from Continental Europe, 38.3% from Americas, 37.2% from Asia, Africa & Australasia and 7.5% from UK

Human Capital Metrics

Embed Graph
Show all human capital metrics

AstraZeneca Online and Social Media Presence

Embed Graph

AstraZeneca Company Culture

  • Overall Culture

    B

    70/100

  • CEO Rating

    B

    70/100

  • Compensation

    A+

    81/100

Learn more on Comparably

AstraZeneca News and Updates

AstraZeneca sales, earnings boosted by stockpiling

AstraZeneca PLC said Wednesday that sales and earnings climbed in the first quarter, becoming the latest major pharmaceutical company to benefit from medicine stockpiling amid the coronavirus pandemic.

AstraZeneca's Wuxi life science incubator now open

AstraZeneca said on Tuesday that its life science incubation facility in Wuxi is officially open and 10 domestic and overseas companies have moved in and started operations there.

AstraZeneca shares surge on Phase 3 trial success of lung cancer drug

Shares of AstraZeneca shot up nearly 7% in London as the pharmaceutical said a phase III trial for its Tagrisso drug showed "overwhelming efficacy." AstraZeneca said it is the first global trial for an EGFR inhibitor to show statistically significant and clinically meaningful benefit in adjuvant t…

AstraZeneca to Test New Cancer Medicine in Covid-19 Battle

Astra to Test Cancer Medicine For Lethal Covid-19 Reaction

AstraZeneca, Merck Drug Approved for Painful Childhood Ailment

AstraZeneca, Merck Drug Approved for Painful Childhood Ailment

Vidscrip Announces Groundbreaking Collaboration with AstraZeneca to Address COVID-19

MINNEAPOLIS, April 7, 2020 /PRNewswire/ -- Vidscrip is the leading digital communications platform that allows physicians to pre-record video messages for patients. Today, Vidscrip announced that it has launched an important new program, in collaboration with AstraZeneca, one of the...
Show more

AstraZeneca Frequently Asked Questions

  • When was AstraZeneca founded?

    AstraZeneca was founded in 1999.

  • Who are AstraZeneca key executives?

    AstraZeneca's key executives are Pascal Soriot, Mark Cobbold and Anand Subramony.

  • How many employees does AstraZeneca have?

    AstraZeneca has 70,600 employees.

  • What is AstraZeneca revenue?

    Latest AstraZeneca annual revenue is $24.4 b.

  • What is AstraZeneca revenue per employee?

    Latest AstraZeneca revenue per employee is $345.4 k.

  • Who are AstraZeneca competitors?

    Competitors of AstraZeneca include Novartis, GlaxoSmithKline and Amgen.

  • Where is AstraZeneca headquarters?

    AstraZeneca headquarters is located at Francis Crick Ave, Trumpington, Cambridge.

  • Where are AstraZeneca offices?

    AstraZeneca has offices in Cambridge, London, Luton, Park Estate and in 241 other locations.

  • How many offices does AstraZeneca have?

    AstraZeneca has 258 offices.